Currently undergoing Phase I clinical trials, a third-generation recombinant humanized agonistic antibody targets DR5. This antibody achieves selective DR5 agonism, favoring the apoptosis of cancer cells while sparing normal cells (Subbiah et al., 2023; Newton, 2023; Classic, 2018a). The gene discussed is TNFRSF10B; the disease is cancer.